We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new and old optimized drugs are central to any control strategy and the fastest route to tuberculosis elimination.
Latest news
PanACEA General Assembly
In the quarterly meeting of the General Assembly of PanACEA on 23rd of September an update was given on the progress of the trials and the capacity development plans. The operational teams and study teams are working hard for the final preparations of the BTZ043 trial that will start in November of 2019. This phase…
12th International Workshop on Clinical Pharmacology of Tuberculosis Drugs
On Tuesday 10th of September the 12th edition of the International Workshop on Pharmacology of Tuberculosis Drugs took place in London. The annual platform brings together experts to share the latest findings in the field of TB clinical pharmacology. From this perspective, Lindsey te Brake presented the PK findings of the PanACEAII HR1 trial. Elin…
Read more 12th International Workshop on Clinical Pharmacology of Tuberculosis Drugs
INTERTB 2019
The yearly INTERTB symposium, organised by dr. Amina Jindani, was held in London on Monday 9th of September. Martin Boeree presented the results of the PanACEAII HR1 trial and opened the discussion on the optimal dose of rifampicin. Other speakers were, amongst others, consortium members Patrick Phillips, Timothy McHugh and Gerry Davies.
SimpliciTB General Assembly
The first formal meeting of SimpliciTB General Assembly (GA) took place on the 25th of July. We had an excellent representation of the collaborating groups with 20 attendees from 9 countries. The Executive Group (EG) has been established with colleagues from South Africa, Tanzania, and our new partners from Uganda, Mozambique, Malawi and Gabon joining the group. A…
PanACEA General Assembly
On the 1st of July the PanACEA General Assembly met by teleconference for its quarterly gathering. The program of the project is progressing as the preparations for the next trials are ongoing and the Operational Teams are meeting on a regular basis. The Expertise Cores are involved as well, rolling out the MBL assay, building…